The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.
 
Wael A. Harb
Research Funding - Horizon Oncology Research
 
Virginie Cerec
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
Travel, Accommodations, Expenses - PsiOxus Therapeutics
 
Hilary McElwaine-Johnn
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics; Vantia
Stock and Other Ownership Interests - Vantia
Consulting or Advisory Role - PsiOxus Therapeutics
 
Brian Champion
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Simon Alvis
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Nitin Jain
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Christopher Ellis
Employment - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
 
Kerry Fisher
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics
Research Funding - PsiOxus Therapeutics
Patents, Royalties, Other Intellectual Property - PsiOxus Therapeutics
Travel, Accommodations, Expenses - PsiOxus Therapeutics
 
John William Beadle
Employment - PsiOxus Therapeutics
Leadership - PsiOxus Therapeutics
Stock and Other Ownership Interests - PsiOxus Therapeutics